3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Melanoma
117
Carcinoma, Non-Small-Cell Lung
102
Carcinoma, Renal Cell
70
Colorectal Neoplasms
46
Neoplasm Metastasis
41
Squamous Cell Carcinoma of Head and Neck
39
Carcinoma, Hepatocellular
38
Neoplasms
36
Lung Neoplasms
34
Stomach Neoplasms
33
Urinary Bladder Neoplasms
22
Carcinoma, Transitional Cell
21
Hodgkin Disease
20
Brain Neoplasms
20
Pancreatic Neoplasms
18
Ovarian Neoplasms
18
Prostatic Neoplasms
17
Head and Neck Neoplasms
16
Colonic Neoplasms
16
Skin Neoplasms
15
Triple Negative Breast Neoplasms
14
Sarcoma
14
Glioblastoma
14
Adenocarcinoma Of Esophagus
14
Carcinoma, Merkel Cell
13
Small Cell Lung Carcinoma
12
Rectal Neoplasms
12
Esophageal Neoplasms
12
Breast Neoplasms
12
Uveal Melanoma
11
Interventions
belzutifan
4
Everolimus
2
spartalizumab
1
palbociclib
1
lenvatinib
1
gallium Ga 68 dotatate
1
cabozantinib
1
Nivolumab
1
Blood Specimen Collection
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
von Hippel-Lindau Disease
×
Nivolumab
×
1 year
×
Clear all
NCT07405164
2026-05-29
MK-6482-043
Merck Sharp & Dohme LLC
Phase 3
Recruiting
450 enrolled